EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif^® (interferon beta-1a), as well as in endocrinology, with Saizen^® (somatropin (rDNA origin) for injection), Serostim^® (somatropin (rDNA origin) for injection) and Zorbtive™ (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f^® (follitropin alpha for injection), Luveris^® (lutropin alfa for injection) and Ovidrel^® Prefilled Syringe (choriogonadotropin alpha injection). EMD Serono is also focused on oncology and autoimmune and inflammatory diseases as emerging areas of expertise. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with more than 1,100 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.